证券简称：皖仪科技 证券代码：688600 2025 年 4 月 | 一、释义 | 3 | | --- | --- | | 二、声明 | 4 | | 三、基本假设 | 5 | | 四、独立财务顾问意见 | 6 | | （一）本次限制性股票激励计划的审批程序 6 | | | （二）本次作废处理部分限制性股票的原因和数量 9 | | | （三）结论性意见 10 | | | 五、备查文件及咨询方式 | 11 | | （一）备查文件 11 | | 一、释义 上海荣正企业咨询服务（集团）股份有限 公司 关于安徽皖仪科技股份有限公司 2021 年限制性股票激励计划作废处理部分 限制性股票相关事项 之 独立财务顾问报告 3 / 11 1. 上市公司、公司、皖仪科技：指安徽皖仪科技股份有限公司。 2. 股权激励计划、限制性股票激励计划、本激励计划：指《安徽皖仪科技股份 有限公司 2021 年限制性股票激励计划（草案修订稿）》。 3. 限制性股票、第二类限制性股票：符合激励计划授予条件的激励对象在满足 相应的获益条件后分次获得并登记的公司 A 股普通股股票。 4. 股本总额：指公司股东大会审议通过本计划时公司已发行的股本总额。 ...

审计报告 安徽皖仪科技股份有限公司 容诚审字[2025]230Z1313 号 容诚审字[2025]230Z1313 号 容诚会计师事务所（特殊普通合伙） 总所：北京市西城区阜成门外大街 22 号 1 幢 10 层 1001-1 至 1001-26 (100037) TEL:010-6600 1391 FAX:010-6600 1392 E-mail:bj@rsmchina.com.cn https://www.rsm.global/china/ 安徽皖仪科技股份有限公司全体股东： 一、审计意见 我们审计了安徽皖仪科技股份有限公司（以下简称皖仪科技）财务报表，包 括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度的合并及母公司利润 表、合并及母公司现金流量表、合并及母公司所有者权益变动表以及相关财务报 表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制， 公允反映了皖仪科技 2024 年 12 月 31 日的合并及母公司财务状况以及 2024 年度 的合并及母公司经营成果和现金流量。 容诚会计师事务所(特殊普通合伙) 中国·北京 目 录 | 序号 | 内 容 | ...

非经营性资金占用及其他关联资金 往来情况专项说明 安徽皖仪科技股份有限公司 容诚专字[2025]230Z0932 号 容诚会计师事务所(特殊普通合伙) 中国·北京 关于安徽皖仪科技股份有限公司 容诚会计师事务所（特殊普通合伙） 总所：北京市西城区阜成门外大街 22 号 1 幢 10 层 1001-1 至 1001-26 (100037) TEL:010-6600 1391 FAX:010-6600 1392 E-mail:bj@rsmchina.com.cn https://www.rsm.global/china/ 非经营性资金占用及其他关联资金往来情况专项说明 容诚专字[2025]230Z0932 号 容诚会计师事务所 （特殊普通合伙） 中国注册会计师： 孔晶晶 安徽皖仪科技股份有限公司全体股东： 我们接受委托，依据中国注册会计师审计准则审计了安徽皖仪科技股份有限 公司（以下简称皖仪科技）2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度的合并及母公司利润表、合并及母公司现金流量表和合并及母公司所有者权 益变动表以及财务报表附注，并于 2025 年 4 月 28 日出具了容诚审字 [ ...

募集资金存放与实际使用情况鉴证报告 安徽皖仪科技股份有限公司 容诚专字[2025]230Z0931 号 容诚会计师事务所(特殊普通合伙) 中国·北京 目 录 | 序号 | 内 容 | 页码 | | --- | --- | --- | | 1 | 募集资金存放与实际使用情况鉴证报告 | 1-2 | | 2 | 募集资金存放与实际使用情况的专项报告 | 3-8 | 募集资金存放与实际使用情况鉴证报告 容诚专字[2025]230Z0931 号 容诚会计师事务所（特殊普通合伙） 总所：北京市西城区阜成门外大街 22 号 1 幢 10 层 1001-1 至 1001-26 (100037) TEL:010-6600 1391 FAX:010-6600 1392 E-mail:bj@rsmchina.com.cn https://www.rsm.global/china/ 安徽皖仪科技股份有限公司全体股东： 我们审核了后附的安徽皖仪科技股份有限公司（以下简称皖仪科技）董事会编 制的 2024 年度《募集资金存放与实际使用情况的专项报告》。 一、 对报告使用者和使用目的的限定 本鉴证报告仅供皖仪科技年度报告披露之目的使用， ...

国新证券股份有限公司 关于安徽皖仪科技股份有限公司 募投项目延期事项的核查意见 经中国证券监督管理委员会《关于同意安徽皖仪科技股份有限公司首次公开发行股 票注册的批复》（证监许可【2020】999 号）核准，公司向社会公众公开发行人民币普 通股（A 股）3,334 万股，每股面值 1.00 元，每股发行价格为 15.50 元。本次公开发行 募集资金总额为 51,677.00 万元，扣除总发行费用 5,846.76 万元（不含增值税），募集 资金净额为 45,830.24 万元。上述募集资金到位情况已经容诚会计师事务所（特殊普通 合伙）审验，并于 2020 年 6 月 30 日出具了"容诚验字[2020]230Z0109 号"《验资报告》。 公司对募集资金采取了专户存储制度，设立了相关募集资金专项账户。募集资金到 账后，已全部存放于该募集资金专项账户内，并与保荐机构、存放募集资金的银行签署 了募集资金三方监管协议。具体情况详见 2020 年 7 月 2 日披露于上海证券交易所网站 （www.sse.com.cn）首次公开发行股票科创板上市公告书。 二、募集资金投资项目及使用情况 截至 2024 年 12 月 3 ...

内部控制审计报告 安徽皖仪科技股份有限公司 容诚审字[2025]230Z1314 号 容诚会计师事务所(特殊普通合伙) 中国·北京 内部控制审计报告 总所：北京市西城区阜成门外大街 22 号 1 幢 10 层 1001-1 至 1001-26 (100037) TEL:010-6600 1391 FAX:010-6600 1392 E-mail:bj@rsmchina.com.cn https://www.rsm.global/china/ 容诚审字[2025]230Z1314 号 安徽皖仪科技股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了安徽皖仪科技股份有限公司（以下简称皖仪科技）2024 年 12 月 31 日的 财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部 控制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是皖仪 科技董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表 审计意见，并对注意到的非财务报告内部控制 ...

2024 年度营业收入扣除情况的 专项审核报告 安徽皖仪科技股份有限公司 容诚专字[2025]230Z1329 号 容诚会计师事务所(特殊普通合伙) 中国·北京 | | | | 序号 | 内 | 容 | 页码 | | --- | --- | --- | --- | | 1 | 营业收入扣除情况的专项审核报告 | | 1-2 | | 2 | 营业收入扣除情况表 | | 3 | 容诚会计师事务所（特殊普通合伙） 总所：北京市西城区阜成门外大街 22 号 1 幢 10 层 1001-1 至 1001-26 (100037) TEL:010-6600 1391 FAX:010-6600 1392 E-mail:bj@rsmchina.com.cn https://www.rsm.global/china/ 关于安徽皖仪科技股份有限公司 2024 年度营业收入扣除情况的专项审核报告 容诚专字[2025]230Z1329 号 安徽皖仪科技股份有限公司全体股东： 我们接受委托，按照中国注册会计师审计准则审计了安徽皖仪科技股份有限 公司（以下简称皖仪科技）2024 年度财务报表，并于 2025 年 4 月 28 日出具了容 ...

安徽天禾律师事务所 法律意见书 关于安徽皖仪科技股份有限公司 ANHUI TIANHE LAW OFFICE 地址：合肥市濉溪路 278 号财富广场 B 座东楼 16 层 电话：（0551）62642792 传真：（0551）62620450 1 2021 年限制性股票激励计划作废处理部分限制性股票 之 法律意见书 安徽天禾律师事务所 法律意见书 安徽天禾律师事务所 关于安徽皖仪科技股份有限公司 2021 年限制性股票激励计划作废处理部分限制性股票 之法律意见书 天律意 2025 第 00910 号 致：安徽皖仪科技股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民共和国 公司法》（以下简称"《公司法》"）、中国证券监督管理委员会（以下简称"证监 会"）《上市公司股权激励管理办法》（以下简称"《管理办法》"）《上海证券交易 所科创板股票上市规则》（以下简称"《上市规则》"）及《科创板上市公司自律监 管指南第 4 号——股权激励信息披露》（以下简称"《披露指南》"）等法律、 行政法规、部门规章及规范性文件（以下统称"法律法规"）和《安徽皖仪科技 股份有限公司章程》（以下简称"《公司 ...

Financial Performance - The company's operating revenue for 2024 was CNY 740.32 million, a decrease of 5.92% compared to CNY 786.87 million in 2023[25]. - The net profit attributable to shareholders for 2024 was CNY 14.41 million, down 67.11% from CNY 43.81 million in 2023[25]. - The cash flow from operating activities for 2024 decreased by 66.96% to CNY 32.19 million, compared to CNY 97.42 million in 2023[25]. - Basic earnings per share for 2024 were CNY 0.11, a decline of 66.67% from CNY 0.33 in 2023[26]. - The company's total assets at the end of 2024 were CNY 1.20 billion, down 8.93% from CNY 1.32 billion at the end of 2023[25]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY -1.97 million in 2024, a decline of 107.95% from CNY 24.85 million in 2023[25]. - The company's gross profit margin decreased by 2.09 percentage points to 45.60% compared to the previous year[102]. - The company reported a significant decline in sales volume for industrial detection instruments, down 25.87% year-on-year, influenced by reduced demand in the new energy market[104]. - The online monitoring instruments saw a sales volume decrease of 22.08% year-on-year, attributed to intense market competition[104]. Research and Development - Research and development expenses accounted for 19.82% of operating revenue in 2024, a decrease of 1.33 percentage points from 21.15% in 2023[26]. - The total R&D investment for the year was approximately ¥146.77 million, a decrease of 11.81% compared to the previous year[74]. - The company continues to maintain a high level of R&D investment, impacting short-term profits but aimed at long-term growth[28]. - The company has established a first-class R&D team with expertise across various fields, enhancing R&D efficiency and innovation capabilities[87]. - The company has developed core technologies including ultra-low emission online monitoring technology and volatile organic compounds (VOCs) analysis technology, which are at the product stage and are domestically leading[67]. - The company has developed advanced technologies such as high-reliability sealing and decomposition devices, and various detection technologies, all of which are at the product stage[68]. - The company has made significant advancements in software technologies, including cloud-native applications and deep learning intelligent analysis technologies, all leading domestically[68]. - The company is focusing on continuous R&D investment and innovation to meet the high standards required for precision instruments, which have significant technical barriers to entry[55]. Market Strategy and Expansion - The company is focusing on expanding its market presence in 23 countries, including Ecuador, Peru, and Mexico, to enhance its international competitiveness[42]. - The company is actively participating in the Guangdong Alliance bulk procurement for ultrasonic knives, aiming to strengthen its market position in the medical device sector[41]. - The company is focusing on expanding its market presence in the semiconductor and new energy sectors, with significant growth potential anticipated in the coming years[79]. - The company is committed to becoming a competitive player in the precision scientific instruments and life health sectors, with a vision of being a respected Chinese enterprise[132]. - The company is strategically positioned for future growth through its investment in new technologies and market expansion efforts[152]. Corporate Governance - The company has established a comprehensive governance structure in compliance with relevant laws and regulations, ensuring effective operation and accountability[140]. - The independent directors actively participated in decision-making, enhancing the board's professionalism and efficiency[141]. - The company has no significant issues regarding independence from its controlling shareholders, maintaining a clear separation in operations and finances[143]. - The company’s governance practices align with the standards set by the China Securities Regulatory Commission and the Shanghai Stock Exchange[143]. - The company held 6 board meetings during the year, with 5 conducted via communication methods and 1 combining on-site and communication methods[162]. Shareholder Engagement and Profit Distribution - The company plans to distribute a cash dividend of 1.00 CNY per 10 shares for the 2024 fiscal year, amounting to approximately 12,532,241.10 CNY, which accounts for 86.99% of the projected net profit attributable to shareholders[180][183]. - The cumulative cash dividend over the last three fiscal years amounts to 65,118,805.90 CNY, with an average net profit of 35,342,918.44 CNY, resulting in a cash dividend ratio of 184.25%[185]. - The company has maintained a robust communication process with minority shareholders regarding profit distribution proposals[181]. - The company ensures that independent directors fulfill their responsibilities and that minority shareholders have opportunities to express their opinions on profit distribution[181]. Financial Position and Investments - The company reported a significant improvement in operational efficiency, contributing to a 46.18% increase in the financial director's shareholding[150]. - The company's cash and cash equivalents increased by 73.45% to 88.28 million yuan, primarily due to the recovery of financial products[115]. - The company's investment activities generated a net cash flow of 77.64 million yuan, a significant increase compared to the previous year's negative cash flow[113]. - The company has a strong after-sales service team, enhancing market competitiveness and customer satisfaction[86]. - The company is exposed to financial risks if government support for its industry decreases, potentially affecting its operating performance[92]. Talent Development and Employee Engagement - The company is committed to talent development, optimizing its workforce structure and enhancing its training systems to attract and retain talent[46]. - The company has established a competitive salary system based on performance evaluation, ensuring key talents are compensated favorably in the market[171]. - A training plan for 2024 is in place, focusing on new hires and existing employees, with specialized training for key positions to ensure competency[172]. - The overall employee engagement in stock ownership has risen, with a notable 34.22% increase for Wei Binsong, indicating a positive shift in company culture[150]. Risk Management - The company has detailed various risks and countermeasures in the report, which can be found in the "Risk Factors" section[4]. - The company faces risks related to market demand fluctuations due to macroeconomic conditions, which may impact future revenue growth[91]. - The company is focusing on maintaining a high proportion of R&D investment, which has led to a negative taxable income in recent years[97].

Financial Performance - The company's operating revenue for Q1 2025 was CNY 134,286,929.36, representing a 16.87% increase compared to CNY 114,906,354.26 in the same period last year[4] - The net profit attributable to shareholders was a loss of CNY 5,450,922.09, an improvement from a loss of CNY 33,616,386.19 in the previous year[4] - The basic and diluted earnings per share were both negative CNY 0.04, an improvement from negative CNY 0.25 in the same period last year[4] - Net profit for Q1 2025 was -¥5.45 million, an improvement from -¥33.62 million in Q1 2024, indicating a significant reduction in losses[20] Cash Flow - The net cash flow from operating activities was a negative CNY 24,458,924.76, worsening from a negative CNY 14,945,672.69 year-on-year[4] - Cash flow from operating activities showed a net outflow of -¥24.46 million in Q1 2025, compared to -¥14.95 million in Q1 2024[24] - Cash inflow from investment activities was ¥115.89 million in Q1 2025, a decrease from ¥206.91 million in Q1 2024[24] - Cash outflow from investment activities totaled ¥133.05 million in Q1 2025, down from ¥149.18 million in Q1 2024[24] - The net increase in cash and cash equivalents was -$28,976,358.19, a significant decline from an increase of $54,317,165.21 in the prior period[25] - The ending balance of cash and cash equivalents was $56,241,866.39, down from $104,036,896.49, representing a decrease of approximately 46.0%[25] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,179,462,076.18, a decrease of 1.86% from CNY 1,201,819,195.09 at the end of the previous year[5] - The equity attributable to shareholders decreased by 6.68% to CNY 739,360,356.23 from CNY 792,297,427.81[5] - Total liabilities increased to ¥440.10 million in the latest reporting period from ¥409.52 million previously, indicating a rise in financial obligations[17] - Current liabilities decreased to RMB 353,429,580.57 from RMB 376,336,646.15, showing a reduction of approximately 6.06%[16] Research and Development - Research and development expenses totaled CNY 35,440,733.04, down 19.06% from CNY 43,785,860.20, with R&D expenses accounting for 26.39% of operating revenue, a decrease of 11.72 percentage points[5] - Research and development expenses for Q1 2025 were ¥35.44 million, down 19% from ¥43.79 million in Q1 2024[20] Operational Strategy - The company plans to continue focusing on improving operational efficiency and reducing costs to enhance profitability in future quarters[7] Shareholder and Financing Activities - The company has no significant changes in the shareholder structure or related party transactions during the reporting period[12] - The company raised ¥60 million through borrowings in Q1 2025, compared to ¥40 million in Q1 2024, reflecting increased financing activities[24] - Cash flow from financing activities totaled $48,362,784.97, an increase from $28,466,172.98 in the previous period, reflecting a growth of approximately 70.0%[25]